• Submit to Pharmaceuticals Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [146 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Nechansky, A
• Koller, I
• Kircheis, R
• [+] on Google Scholar
• Nechansky, A
• Koller, I
• Kircheis, R
• [+] on PubMed
• Nechansky, A
• Koller, I
• Kircheis, R

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceuticals 2010, 3(6), 1887-1891; doi:10.3390/ph3061887

Commentary

In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)

Andreas Nechansky ^1,2,* , Iris Koller ²  and Ralf Kircheis ^1,3

¹ Meridian Biopharmaceuticals GmbH, Brunnerstrasse 59, 1230 Wien, Austria ² Vela Pharmazeutische Entwicklung und Laboranalytik GmbH, Brunnerstrasse 59, 1230 Wien, Austria ³ Virologik GmbH, Henkestrasse 91, 91052 Erlangen, Germany

* Author to whom correspondence should be addressed.

Received: 29 April 2010; in revised form: 31 May 2010 / Accepted: 9 June 2010 / Published: 10 June 2010

(This article belongs to the Special Issue Monoclonal Antibody)

Download PDF Full-Text [146 KB, uploaded 10 June 2010 11:44 CEST]

Abstract: To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146–157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that — besides the Glycart and the Biowa approach to generate de-fucosylated antibodies — innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile.

Keywords: therapeutic antibodies; glyco-modified IgG; ADCC; CDC; Fc -γRIII

Article Statistics

Cite This Article